The US Army has selected Daxor for a contract award to develop a blood volume analyser to enhance combat casualty care.
Daxor is an investment and biotechnology company with innovative medical instrumentation that focuses on blood volume measurement.
The company has been selected under the US Department of Defense’s small business innovative research (SBIR) programme.
Daxor chief executive officer Michael Feldschuh said: “Haemorrhage is the primary cause of death in about 30% of injured soldiers.
“Direct blood volume measurement has been shown to improve outcomes in a broad range of acute and chronic medical conditions. Our existing technology platform and patent portfolio is an ideal foundation for developing a rapid, rugged, portable blood volume analyser that can improve prehospital resuscitation on the battlefield, potentially saving many lives.”
Under the agreement, Daxor will be responsible for developing and demonstrating a new prototype blood volume analyser for military use.
The company has been selected for the first time by the US Army for the SBIR contract award to meet the critical requirements of the service.
Daxor chief scientific officer Jonathan Feldschuh said: “This is an exciting additional opportunity to push our research and development programme forward.
“We are focused on making volume measurement easier and quicker to perform, whether in a hospital lab, on the battlefield, or at the patient bedside.”
Based on the fundamental concept of the indicator dilution technique, blood volume analysis is a simple test used to measure how much blood a patient has in their body at that time.